Followers | 31 |
Posts | 3857 |
Boards Moderated | 1 |
Alias Born | 09/24/2012 |
![](http://investorshub.advfn.com/images/default_ih_profile2_4848.jpg?cb=0)
Friday, June 07, 2013 2:03:20 PM
Also, this older iHub post contains relevant info:
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=25699481
This was posted by i believe "jazzbeerman", PPHM Board post # is 20084 and reads as follows:
actually it's the drug bavituximab, as well as other PPHM mabs, that are being used by Gates and CHAVI researchers, researchers that specifically include our Thorpe. Thorpe is a member of the Gates CAVD - Collaboration for HIV/AIDS Vaccine Discovery. Thorpe is working (with Bavi and his other PPHM mabs) directly under Haynes, (Director of CHAVI, and also recipient of a big Gates CAVD grant which is funding Thorpe's and other's work with bavituxmab and other PPHM mabs), as a part of Haynes Vaccine Discovery Consortia.
http://humanvaccine.duke.edu/modules/grant_spt/index.php?id=11
glad I could clear THAT up for ya :)
re: Bavi's MOA - I make that point to further illustrate that recently the general thrust of the overall research into HIV therapy and vaccines, is moving much more in line with Bavi's MOA. It's fascinating, and amazing. (read the Haynes abstract again, or read it for the first time. It's pretty obvious if you just do the reading).
Realize that Haynes is the Director, the top leader, of NIH's whole $300 million CHAVI program, which, along with the Gates $287 million CAVD, both fall under what's called the Global HIV Vaccine Enterprise.
Realize that the reason the money got thrown at Haynes, (crudely put but accurate enough), was due to his MAJOR discovery of the broadly-neutralizing HIV abs found in people naturally stuck to host-cell phospholipids...
and understand that Haynes is the one talking about abundant PS downregulating the immune system's fight against HIV
and understand that Haynes and others in CHAVI / Gates are working with and generating data on Bavituximab and other PPHM mabs that fall under PPHM's anti-phospholipid platform in his experiments.
Let there be no confusion about that.
re: Hearing "PPHM", "Bavituximab", (among other things),
I think you will. It's sounding like the work has progressed far enough for them to publish, and discuss results.
- and the two big annual conferences are coming up this quarter.
As for other, as you hint at - non-PPHM anti-phosphatidylserine mabs, - you simply need to read the CHAVI clinical protocols that I often post.
in CHAVI 005, they're looking for broadly neutralizing HIV antibodies which target host-cell phospholipids in lupus patients.
in CHAVI 006, they're looking for broadly neutralizing HIV antibodies which target host-cell phospholipids in syphilis patients.
etc...
All this is as a model to see if it's worth it to try to design a vaccine that elicits this type of ab in people.
as for "Bavi's MOA" -
in CHAVI 012, (the newest protocol), they're looking into how PS-exposing microparticles may blunt a successful immune response early in HIV infection.
etc, etc....
Remember -
The point of CHAVI & Gates CAVD work is to eventually create a successful VACCINE.
A vaccine is a preventative for something BEFORE your body encounters it.
Bavi and other PPHM mabs are being used to see if it's "worth it" to try to design an immunogen that creates 'natural bavi' in one's body, to stay on the lookout for HIV's potential arrival.
The CHAVI / Gates research may or may not be successful in CREATING A VACCINE. If they are successful, it will take serious time, and serious money.
The "take-away" for PPHM is that -
Any VACCINE work that CHAVI / Gates does with PPHM's mabs in their quest to see if they protect from HIV infection, (or alter the immune response in a beneficial way), is IMMEDIATELY applicable for PPHM as a THERAPEUTIC.
The other obvious and extremely important take-away is that here we have the best researchers in the world working with our specific drugs, working on one of the worst epidemics in history, and those researchers may validate PPHM's anti-PS platform as a whole as a successful therapeutic against that epidemic, and those researchers may validate PPHM's anti-PS platform in a very broad sense I might add, (with implications for therapy - due to Bavi's MOA - for all viral disease, tumors, PS-dependent parasitic disease, etc...)
(This is why you now see the name Robert Sidwell (top flu doc) also affiliated with PPHM), among others.
Sidwell has Bavituximab and likely other PPHM PS targeting molecules...
You also need to realize WHY it's so imposrtant for these 'top docs' to validate the targeting of host-cell phospholipids in general - because it's a pretty big 'shift' in immunotherapeutic thinking...
As I've been saying -
Bavi acts as a therapeutic vaccine for what you've got in ya.
All that data that CHAVI / Gates researchers have been accumulating, has been guiding, and will continue to guide, PPHM's anti-phosphatidylserine antiviral therapeutic (and therapeutic vaccine) research.
Now, it is beyond the scope of the topic of this post, but it is also looking like if and when any HIV vaccine is arrived at, Bavi will again play a role as an ADJUVANT. Due to Bavi's MOA, it should make any vaccine more effective. It should facilitate any immunogen to be 'recognized' more easily.
I hope you realize that Bavi lasts about three days in a person. If you don't have HIV when you get a shot of Bavi, it won't do anything for you down the road. Part of the vaccine research will likely be using combinations of bavi WITH HIV immunogens, much like Thorpes fabulously successful work that so beautifully isolated and illustrated Bavi's immune-modulating vaccination effect against malignant glioma.
This is all well-documented science, illustrated by numerous specific Bavituximab papers and presentations.
I think things will be getting interesting soon,
keep watching! :)
(but please do some reading)
j
Recent CDMO News
- U.S. Futures Rise Amid Inflation Report Anticipation; Oil Prices Climb on Hurricane Threat and Supply Concerns • IH Market News • 09/09/2024 10:09:14 AM
- Avid Bioservices to Report Financial Results for First Quarter of Fiscal Year 2025 After Market Close on September 9, 2024 • GlobeNewswire Inc. • 09/03/2024 08:05:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/29/2024 08:30:10 PM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 08/28/2024 08:34:04 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 08/28/2024 08:32:18 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 08/28/2024 08:30:28 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:50:20 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/16/2024 11:48:19 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/15/2024 08:40:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/12/2024 08:30:04 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:39 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:02:27 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:01:05 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:54 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/11/2024 09:00:45 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/11/2024 12:23:26 AM
- Avid Bioservices Reports Financial Results for Fourth Quarter and Fiscal Year Ended April 30, 2024 • GlobeNewswire Inc. • 07/02/2024 08:05:04 PM
- Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024 • GlobeNewswire Inc. • 07/01/2024 11:00:21 AM
- Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance • GlobeNewswire Inc. • 05/23/2024 12:05:46 PM
- Avid Bioservices to Participate at Upcoming Investor Conferences • GlobeNewswire Inc. • 05/07/2024 08:05:11 PM
- Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024 • GlobeNewswire Inc. • 04/24/2024 09:25:33 PM
- Avid Bioservices Announces Receipt of Deficiency Notice from Nasdaq Regarding Late Form 10-Q • GlobeNewswire Inc. • 03/20/2024 11:00:10 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 11:30:11 AM
- Avid Bioservices Announces Pricing of Private Placement of Convertible Notes • GlobeNewswire Inc. • 03/07/2024 04:58:48 AM
FEATURED Element79 Gold Corp. Announces Sale of 100% Interest in Elder Creek, North Mill Creek, and Elephant Projects to 1472886 B.C. Ltd. • Sep 9, 2024 9:34 AM
North Bay Resources Commences Gold Shipments, Fran Gold Project, British Columbia; Enters Taber Gold Mine JV, Sierra County, California • NBRI • Sep 9, 2024 9:15 AM
Simple Stock Loans Announces Unique Solutions For Investors Looking for Alternative Liquidity Amidst Recent Small Cap Rally Sep 6, 2024 9:30 AM
Reliant Coffee Debuts at #271 on the Inc. 5000 List of Fastest Growing Companies - Coffee Service Industry Disruptor Brews Up Exponential Growth Sep 5, 2024 11:51 AM
VAYK Confirms Receiving Revenue from First Airbnb Property with 1.4 Million Annual Revenue Goal • VAYK • Sep 4, 2024 9:34 AM
Mawson Finland Limited Expands Known Mineralized Zones at Rajapalot: New Lens Intercepts 21.75 m at 5.25 g/t Gold & 515 ppm Cobalt • MFL • Sep 4, 2024 9:02 AM